GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » ClouDr Group Ltd (HKSE:09955) » Definitions » Sloan Ratio %

ClouDr Group (HKSE:09955) Sloan Ratio % : -4.90% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is ClouDr Group Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

ClouDr Group's Sloan Ratio for the quarter that ended in Dec. 2023 was -4.90%.

As of Dec. 2023, ClouDr Group has a Sloan Ratio of -4.90%, indicating the company is in the safe zone and there is no funny business with accruals.


ClouDr Group Sloan Ratio % Historical Data

The historical data trend for ClouDr Group's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClouDr Group Sloan Ratio % Chart

ClouDr Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
-17.25 -134.43 -132.25 -10.63 -4.90

ClouDr Group Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Sloan Ratio % Get a 7-Day Free Trial -131.12 -81.74 -11.85 12.52 -4.90

Competitive Comparison of ClouDr Group's Sloan Ratio %

For the Medical Distribution subindustry, ClouDr Group's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ClouDr Group's Sloan Ratio % Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, ClouDr Group's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where ClouDr Group's Sloan Ratio % falls into.



ClouDr Group Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

ClouDr Group's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-353.362--153.599
--41.937)/3221.25
=-4.90%

ClouDr Group's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-353.362--153.6
--41.937)/3221.25
=-4.90%

For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data. ClouDr Group's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -170.632 (Jun. 2023 ) + -182.73 (Dec. 2023 ) = HK$-353 Mil.
ClouDr Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -59.446 (Jun. 2023 ) + -94.154 (Dec. 2023 ) = HK$-154 Mil.
ClouDr Group's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -53.389 (Jun. 2023 ) + 11.452 (Dec. 2023 ) = HK$-42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ClouDr Group  (HKSE:09955) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, ClouDr Group has a Sloan Ratio of -4.90%, indicating the company is in the safe zone and there is no funny business with accruals.


ClouDr Group Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of ClouDr Group's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


ClouDr Group (HKSE:09955) Business Description

Traded in Other Exchanges
Address
No. 998 Wenyi West Road (Haichuang Yuan), Wuchang Street, Rooms 501, 5th Floor, Building 12, Yuhang District, Zhejiang Province, Hangzhou, CHN
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. Its offerings include in-hospital solutions, pharmacy solutions, and individual chronic condition management solutions. The company's in-hospital solution consists of sales of medical devices, consumables and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies. It generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
Executives
Trident Trust Company (hk) Limited 2301 Trustee
Data Vantage Development Limited 2201 Interest of corporation controlled by you
Kuang Ming 2201 Interest of corporation controlled by you
Prime Forest Assets Limited 2101 Beneficial owner
Shang Hai Qi Ji Ke Ji He Huo Qi Ye You Xian He Huo
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si
Zhao Yin Guo Ji Jin Rong You Xian Gong Si
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si
Zhao Yin Guo Ji Jin Rong Kong Gu Shen Zhen You Xian Gong Si
Ho Chi Sing 2201 Interest of corporation controlled by you
China Merchants Bank Co., Ltd.
Zhou Quan 2201 Interest of corporation controlled by you
Idg China Venture Capital Fund Gp Iv Associates Ltd. 2201 Interest of corporation controlled by you
Haoyuan Health Limited 2101 Beneficial owner
Yass Jeffrey Steven

ClouDr Group (HKSE:09955) Headlines

No Headlines